Creating the New

Gold Standard
in Brain Health

Altoida is building the world's leading platform to accelerate and improve drug development, research, and care for people with neurological diseases using data captured with a standard smartphone or tablet

CONNECT WITH US

conventional biomarkers & cognitive assessments

Unreliable
Traditional neurological testing is highly subjective and relies on manual scoring and evaluation of symptoms.
Expensive
Biomarkers evaluated through imaging and cerebrospinal fluid require costly capital equipment and clinical analyses.
Inaccessible
Collection of biological samples and measurements of brain function require long in-person visits to clinical sites.

altoida's digital biomarker platform

Reliable
Altoida’s platform extracts multi-modal data to provide the most sensitive measurements and digital biomarkers for neurological diseases.
Affordable
The 10 minute neurological test battery and real-time analysis are completed using only a standard iOS or Android smartphone or tablet.
Accessible
The platform can be used outside of clinical settings and is supported in a diverse variety of global languages.

Our AI-powered platform will enable reliable, accessible, and affordable diagnosis and monitoring of neurological diseases at every phase on the continuum

  • 10-Minute Activity Set

    Immersive augmented reality and motor activities simulate complex real-world tasks to collect the most ecologically valid data right from your personal device.

  • 800 Digital Biomarkers

    Nearly 800 digital biomarkers measured using the smartphone or tablet's sensors to show actionable scores across 13 neurocognitive domains.

  • AI-Driven Prediction

    The world's first fully digital prediction of conversion from Mild Cognitive Impairment to neurological diseases, like Alzheimer's, using artificial intelligence.

10-Minute Activity Set

Immersive augmented reality and motor activities simulate complex real-world tasks to collect the most ecologically valid data right from your personal device.  

800 Digital Biomarkers

Nearly 800 digital biomarkers measured using the smartphone or tablet's sensors to show actionable scores across 11 neurocognitive domains.  

AI-Driven Prediction

The world's first fully digital prediction of conversion from mild cognitive impairment to neurological diseases, like Alzheimer's, using artificial intelligence.  
To learn more about how Altoida can help you manage neurological disease at scale and take charge of your own brain health, contact us today.
CONNECT WITH US

Altoida's Scientific Validation

Altoida wins Breakthrough Designation for development of predictive Alzheimer's diagnostic.

Fierce Biotech | 08/2021

Altoida's Digital Neuro-Signature and the future of population-level brain health management

Nature Digital Medicine | 07/2021

Altoida’s partnership with Eisai to accelerate work towards predictive dementia diagnostics

Medgadget | 07/2021

Evaluation of Altoida’s device and digital biomarkers in measuring activities of daily living

NIH National Library of Medicine | 12/2020

Altoida’s five-year biomarker progression variability for Alzheimer's dementia prediction

NIH National Library of Medicine | 11/2015
read more

We are partnering with leaders in therapeutics, research, and care to revolutionize brain health

Together We Can Revolutionize Brain Health

To learn more about how Altoida is building the precision neurology platform to power early Alzheimer’s disease diagnosis and personalized brain analysis, contact us.
CONNECT WITH US

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021